Dunelm Group (LON:DNLM – Get Free Report) had its price objective raised by analysts at JPMorgan Chase & Co. from GBX 1,140 ($15.27) to GBX 1,170 ($15.67) in a research report issued to clients and investors on Tuesday, LSE.Co.UK reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 2.63% from the company’s previous close.
Several other research firms also recently weighed in on DNLM. Canaccord Genuity Group reissued a “buy” rating and issued a GBX 1,325 ($17.74) target price on shares of Dunelm Group in a report on Tuesday, September 17th. Berenberg Bank boosted their price objective on Dunelm Group from GBX 1,410 ($18.88) to GBX 1,470 ($19.68) and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,060 ($14.19) target price on shares of Dunelm Group in a research report on Thursday, September 12th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 1,220.83 ($16.35).
Read Our Latest Stock Analysis on Dunelm Group
Dunelm Group Stock Down 7.7 %
About Dunelm Group
Dunelm Group plc retails homewares in the United Kingdom. The company offers furniture and beds products, which include bedroom, living room, dining room, and other furniture, as well as bed and mattresses, and sofas and armchairs; bedding products comprising bed linen, dorma, baby and kid's bedding, and duvets, pillows, and protectors; curtains and rugs; and venetian, roller, roman, vertical, and made to measure blinds.
Read More
- Five stocks we like better than Dunelm Group
- Why Invest in 5G? How to Invest in 5G Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 10 Best Airline Stocks to Buy
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Top Biotech Stocks: Exploring Innovation Opportunities
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Dunelm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dunelm Group and related companies with MarketBeat.com's FREE daily email newsletter.